Suppr超能文献

儿科非恶性疾病异基因造血干细胞移植的晚期效应:代理和患者报告的结局。

Late Effects in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation for Nonmalignant Diseases: Proxy- and Patient-Reported Outcomes.

机构信息

Division of Stem cell Transplantation, Department of Pediatrics, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, Netherlands.

Department of Child and Adolescent Psychiatry & Psychosocial Care, Emma Children's Hospital, Amsterdam University Medical Center, Amsterdam, Netherlands.

出版信息

Transplant Cell Ther. 2023 Mar;29(3):186.e1-186.e10. doi: 10.1016/j.jtct.2022.12.024. Epub 2022 Dec 30.

Abstract

Survival rates in pediatric hematopoietic stem cell transplantation (HSCT) for nonmalignant diseases have improved due to advances in conditioning regimens, donor selection, and prophylaxis and treatment of infections and graft-versus-host disease. Insight into the long-term patient-reported outcomes (PROs) after pediatric HSCT for nonmalignant disease is lacking but essential for optimal shared decision making, counseling, and quality of care. The purpose of this research was to determine long-term patient-reported outcomes in allogeneic pediatric HSCT for nonmalignant diseases and to compare these results with Dutch reference data. This single-center cohort study evaluated PROs (PedsQL 4.0, PROMIS item banks), self- or proxy-reported, among patients at ≥2 years after pediatric allogeneic HSCT for nonmalignant disease. Mean scores were compared with those of the Dutch general population. Of 171 eligible patients, 119 participated, for a 70% response rate. The median patient age was 15.8 years (range, 2 to 49 years), and the median duration of follow-up was 8.7 years (range, 2 to 34 years). Indications for HSCT included inborn errors of immunity (n = 41), hemoglobinopathies (n = 37), and bone marrow failure (n = 41). Compared with reference data, significantly lower scores were found in adolescents (age 13 to 17 years) on the Total, Physical Health, and School Functioning PedsQL subscales. Significantly more Sleep Disturbance was reported in children (age 8 to 18 years). On the other hand, significantly better scores were seen on PROMIS Fatigue (age 5 to 7 years) and Pain Interference (age 8 to 18 years) and, in adults (age 19 to 30 years), on Depressive Symptoms and Sleep Disturbance. This study showed better or comparable very long-term PROs in patients after pediatric HSCT for nonmalignant diseases compared with the reference population. Children and adolescents seem to be the most affected, indicating the need for supportive care to prevent impaired quality of life and, more importantly, to amplify their long-term well-being.

摘要

由于预处理方案、供者选择以及感染和移植物抗宿主病的预防和治疗方面的进步,儿科造血干细胞移植(HSCT)治疗非恶性疾病的生存率得到了提高。然而,对于儿科 HSCT 治疗非恶性疾病的患者长期报告的结果(PROs),我们知之甚少,但这对于最佳的共同决策、咨询和护理质量至关重要。本研究的目的是确定所有儿科 HSCT 治疗非恶性疾病患者的长期报告结果,并将这些结果与荷兰参考数据进行比较。这项单中心队列研究评估了≥2 年接受儿科异基因 HSCT 治疗非恶性疾病的患者的 PROs(PedsQL 4.0、PROMIS 项目库),这些数据由患者或其代理人报告。将平均评分与荷兰一般人群进行比较。在 171 名符合条件的患者中,有 119 名患者参与,应答率为 70%。患者的中位年龄为 15.8 岁(范围为 2 至 49 岁),中位随访时间为 8.7 年(范围为 2 至 34 年)。HSCT 的适应证包括先天性免疫缺陷(n=41)、血红蛋白病(n=37)和骨髓衰竭(n=41)。与参考数据相比,青少年(13 至 17 岁)在 PedsQL 总分、身体功能和学校功能子量表上的得分明显较低。儿童(8 至 18 岁)报告的睡眠障碍明显更多。另一方面,在儿童(5 至 7 岁)和青少年(8 至 18 岁)中,PROMIS 疲劳和疼痛干扰的评分明显更好,在成年人(19 至 30 岁)中,抑郁症状和睡眠障碍的评分也更好。这项研究表明,儿科 HSCT 治疗非恶性疾病的患者的长期 PROs 优于参考人群。儿童和青少年似乎受到的影响最大,这表明需要提供支持性护理,以防止生活质量受损,更重要的是,提高他们的长期幸福感。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验